

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**We claim:**

**Claim 1. (Cancelled)**

**Claim 2. (Currently Amended)** The method according to claim [[13]] 14, wherein the growth-factor receptor is epidermal growth factor receptor (EGFR).

**Claim 3. (Cancelled)**

**Claim 4. (Cancelled)**

**Claim 5. (Cancelled)**

**Claim 6. (Cancelled)**

**Claim 7. (Cancelled)**

**Claim 8. (Currently Amended)** The method according to claim 14, ~~wherein the composition is comprising administering to said subject in need thereof~~ a pharmaceutical composition which comprises said antibody and at least one pharmaceutically acceptable carrier, diluent or adjuvant.

**Claim 9. (Cancelled)**

**Claim 10. (Previously Presented)** The method according to claim 13, wherein the cancer is a human cancer.

**Claim 11. (Withdrawn)** A method for identifying and/or characterizing an inhibitor of processes selected from cell proliferation, cell migration, invasivity and anti-apoptosis in a disorder associated with increased G-protein mediated signal transduction, comprising: determining the effect of a test compound on the transactivation of a growth-factor receptor of the EGFR family.

**Claim 12. (Withdrawn)** The method of claim 11, wherein the test compound is selected from low-molecular weight compounds, peptides and proteins, particularly antibodies or antibody fragments.

**Claim 13. (Currently Amended)** A method for the ~~prevention or~~ treatment of cell proliferation, cell migration, invasivity or anti-apoptosis in a cancer,

wherein said cancer is associated with increased G-protein mediated signal transduction and is at least one of colon cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, lung cancer or ovarian cancer,

comprising administering to a ~~subjected subject~~ in need thereof an effective amount of a composition which comprises an antibody which binds to pro-HB-EGF and which blocks the processing of said pro-HB-EGF.

**Claim 14. (Previously Presented)** The method according to claim 13, wherein the antibody inhibits activation of a growth-factor receptor of the EGFR family.

**Claim 15. (Currently Amended)** The method according to claim ~~[[13]]~~ 14, wherein the growth-factor receptor of the EGFR family is HER-2, HER-3 or HER-4.

**Claim 16. (Previously Presented)** The method according to claim 13 for the treatment of cell proliferation, cell migration, invasivity or anti-apoptosis in a cancer.

**Claim 17. (Currently Amended)** A method for the treatment of cell proliferation, cell migration, invasivity or anti-apoptosis in a cancer,

wherein said cancer is associated with increased G-protein mediated signal transduction and is at least one of colon cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, lung cancer or ovarian cancer,

comprising administering to a ~~subjected subject~~ in need thereof an effective amount of a composition which comprises an ~~acceptable carrier, diluent or adjuvant and an~~ antibody which binds to pro-HB-EGF and which blocks the processing of said pro-HB-EGF.